Also known as: hemic lymphatic rating, blood disorder VA rating, sickle cell rating, spleen removal rating, anemia VA disability, lymph node rating, 7700 hypersensitivity angiitis, 7702 agranulocytosis
Have a specific question about Hemic and Lymphatic System VA Disability Ratings?
Ask Our AI AssistantFree. Answers cite their sources, such as 38 CFR, VA.gov and other veterans-benefits references.
This guide provides a comprehensive overview of VA disability ratings for hemic and lymphatic system conditions, including blood disorders, lymph node diseases, spleen removal, and bone marrow transplants. It is based primarily on 38 CFR § 4.117 and related VA rating criteria.
The hemic and lymphatic systems include blood cells, bone marrow, lymph nodes, spleen, and related organs responsible for immune function and blood production. Conditions affecting these systems can be complex and often require specialized treatment such as chemotherapy, bone marrow transplants, or immunosuppressive therapy.
VA rates disabilities related to these systems under 38 CFR § 4.117, which provides diagnostic codes (DCs) and rating criteria based on severity, treatment requirements, and functional impact.
Agranulocytosis is a severe reduction in granulocytes (a type of white blood cell), leading to increased infection risk.
| Rating | Criteria |
|---|---|
| 100% | Requires bone marrow transplant; or infections recurring at least once every 6 weeks (on average) per 12-month period. |
| 60% | Requires intermittent myeloid growth factors (G-CSF or GM-CSF) or continuous immunosuppressive therapy (e.g., cyclosporine) to maintain ANC between 500 and 1000/µl; or infections recurring at least once every 3 months per 12-month period. |
| 30% | Requires intermittent myeloid growth factors to maintain ANC >1000/µl; or infections recurring at least once per 12-month period but less than once every 3 months. |
| 10% | Requires continuous medication (e.g., antibiotics) for control; or intermittent use of myeloid growth factor to maintain ANC ≥1500/µl. |
Notes:
Leukemia is a cancer of blood-forming tissues, including bone marrow.
| Rating | Criteria |
|---|---|
| 100% | Active disease or during a treatment phase. |
| 0% | Chronic lymphocytic leukemia (CLL) or monoclonal B-cell lymphocytosis (MBL), asymptomatic, Rai Stage 0. |
Additional Notes:
Polycythemia vera is a myeloproliferative disorder causing increased red blood cells.
| Rating | Criteria |
|---|---|
| 100% | Requires peripheral blood or bone marrow stem-cell transplant or chemotherapy (including myelosuppressants) for symptom control. |
| 60% | Requires phlebotomy ≥6 times per 12 months or molecularly targeted therapy to control RBC count. |
| 30% | Requires phlebotomy 4-5 times per 12 months or continuous biologic/myelosuppressive therapy (e.g., interferon) to maintain platelets <200,000 or WBC <12,000. |
| 10% | Requires phlebotomy ≤3 times per 12 months or intermittent biologic therapy to maintain blood values within reference range. |
Notes:
Includes disorders such as essential thrombocythemia and myelofibrosis. Ratings depend on severity and treatment but are generally evaluated similarly to polycythemia vera or leukemia.
| Condition | Diagnostic Code | Rating Percentages (%) | Key Rating Factors |
|---|---|---|---|
| Agranulocytosis | 7702 | 10, 30, 60, 100 | ANC levels, infection frequency, treatments |
| Leukemia (except CML) | 7703 | 0, 100 | Active disease, treatment phase, residuals |
| Polycythemia Vera | 7704 | 10, 30, 60, 100 | Phlebotomy frequency, chemo, transplant |
| Chronic Lymphocytic Leukemia | 7703 | 0, 100 | Rai staging, symptoms |
| Sickle Cell Anemia | 7710 | Varies | Crisis frequency and severity |
| Hemophilia | 7711 | Varies | Bleeding episodes, factor replacement needs |
| Hodgkin’s Disease | 7706 | 100 | Active disease or treatment phase |
Veterans with hemic and lymphatic system disorders may experience secondary conditions that can also be service-connected or rated separately:
A: The 100% rating starts on the date of hospital admission for the transplant and continues through treatment and for 6 months after hospital discharge. After 6 months, a VA exam determines the residual rating.
A: The splenectomy itself is not separately rated, but complications such as infections or blood disorders resulting from splenectomy can be rated under appropriate diagnostic codes.
A: A 100% rating continues for 6 months after treatment ends. After that, VA evaluates residuals and assigns a rating based on current symptoms and lab results.
A: Ratings depend on the frequency and severity of sickle cell crises, including hospitalizations and transfusions. Specific criteria are found under DC 7710.
A: Yes, secondary conditions that are caused or aggravated by your primary service-connected condition can be claimed and rated separately.
This guide is intended to assist veterans and their representatives in understanding VA disability ratings for hemic and lymphatic system conditions. For specific case advice, consult a VA-accredited representative or attorney.
Need personalized guidance on Hemic and Lymphatic System VA Disability Ratings?
Ask Veterans Benefits AIAnswers cite their sources, so you can check them. AI can make mistakes.
Information from the Electronic Code of Federal Regulations (ecfr.gov). Check the original source before you rely on it. Original source.
This page is for informational purposes only and is not legal or medical advice. AI-generated answers can contain errors.
Veterans Benefits AI is an independent 501(c)(3) nonprofit. It is not affiliated with or endorsed by the U.S. Department of Veterans Affairs.
© 2026 Veterans Benefits AI